The trimethylamine N-oxide (TMAO) produced by gut microbiota metabolism can activate CD8+ T cell-mediated anti-tumor immunity and enhance the efficacy of immunotherapy in mouse models of triple-negative BC (Wang et al., 2022). Here, CD8A is linked to breast cancer.